Rivermark Medical has filed a notice of an exempt offering of securities to raise $30,041,096.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Rivermark Medical is raising up to $30,041,096.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Adam Kadlec played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Rivermark Medical
Developing a minimally-invasive treatment for Benign Prostatic Hyperplasia (BPH) that rapidly restores urinary function and allows patients an early return to normal, daily life. Rivermark Medical was founded by a practicing urologist to develop the preferred first-line device therapy for BPH, allowing physicians to treat patients safely and efficiently, with minimal discomfort and reduced complications. The FloStent System is the first product Rivermark Medical plans to bring to market.
To learn more about Rivermark Medical, visit http://www.rivermarkmedical.com/
Rivermark Medical Linkedin Page: https://www.linkedin.com/company/rivermark-medical-inc/
Contact:
Adam Kadlec, President and Chief Executive Officer
773-307-9665
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.